decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Appendix E - National Coverage Determinations Manual / TUMOR_ANTIGEN_BY_IMMUNOASSAY_CA_19
Subscribe or sign in to view the full article.
Article Overview
This policy article explains Medicare national coverage guidance for CA 19-9 tumor antigen testing, including the general clinical context in which the test is considered relevant and the types of situations the policy addresses. It is intended for coders, billing staff, and clinical documentation teams who need to understand coverage scope for tumor marker testing in oncology care.
Why This Topic Matters
Understanding this coverage policy helps users determine whether the article is relevant to documentation, ordering patterns, and billing for tumor marker testing in established cancer care settings.
Article Sections
-
Tumor Antigen By Immunoassay CA 19-9
Introduces the policy topic, revision information, and the general purpose of tumor marker immunoassay coverage guidance. It frames the article around CA 19-9 as a covered subject of review.
-
Indications
Summarizes the clinical situations addressed by the policy, including follow-up and monitoring of established malignancy. It focuses on the broad context in which tumor markers are discussed.
-
Limitations
Describes the broad coverage limitations and circumstances outside the policy’s intended scope. It addresses situations in which the service is not covered and general monitoring-related use.
What You Will Learn
- The general Medicare coverage context for CA 19-9 tumor antigen testing
- The broad clinical scenarios discussed in the policy
- The kinds of limitations associated with tumor marker testing coverage
- How the article frames use of the test in oncology follow-up
Who Should Read This
- Medical coders
- Billing specialists
- Compliance staff
- Clinical documentation specialists
- Oncology practices
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com